• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [17565 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use of immunoglobulins in hematology]
2020     NIHR Health Technology Assessment programme Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use of immunoglobulins in clinical immunology]
2020     NIHR Health Services and Delivery Research programme Optimising acute care for people with dementia: a mixed-methods study
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: use of sedation and general anesthesia in pediatric dental care]
2020     NIHR Health Services and Delivery Research programme Dementia and cognitive impairment in the older prison population of England and Wales: identifying individual need and developing a skilled, multi-agency workforce to deliver targeted and responsive services
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: the therapeutic value of hyperbaric oxygen (HBO) on children with cerebral palsy]
2020     Austrian Institute for Health Technology Assessment (AIHTA) Genetic testing in the context of familial hypercholesterolaemia management. Organisational and ethical implications (part 1), and economic aspects (part 2)
2020     Austrian Institute for Health Technology Assessment (AIHTA) [Lung cancer screening in risk groups]
2020     NIHR Health Services and Delivery Research programme Access to primary and community health-care services for people 16 years and over with intellectual disabilities: a mapping and targeted systematic review
2020     Basque Office for Health Technology Assessment (OSTEBA) [Efficacy and safety of mechanical thrombectomy in the treatment of patients with ischaemic stroke beyond 6 hours after onset or with an unknown time of onset]
2020     Ontario Health Proton beam therapy for cancer
2020     Austrian Institute for Health Technology Assessment (AIHTA) Lung cancer screening in risk groups: a review-update of the economic evidence (Part II)
2020     Basque Office for Health Technology Assessment (OSTEBA) [Neonatal hearing screening programmes: A systematic review of economic evaluation studies and descriptive analysis of Spanish regional programmes]
2020     Ontario Health Transcatheter aortic valve implantation in patients with severe aortic valve stenosis and low surgical risk
2020     Ontario Health Automated CT perfusion imaging to aid in the selection of patients with acute ischemic stroke for mechanical thrombectomy
2020     Ontario Health Home narrowband ultraviolet B phototherapy for photoresponsive skin conditions
2020     Ontario Health Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: acute exacerbation of chronic obstructive pulmonary disease]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: The Argus II retinal implant]
2019     NIHR Health Technology Assessment programme Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: approach to managing access to cancer care: a review of the literature and practices]
2019     NIHR Health Technology Assessment programme Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model
2019     NIHR Health Technology Assessment programme Uterotonic drugs to prevent postpartum haemorrhage: a network meta-analysis
2019     NIHR Health Technology Assessment programme Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation
2019     NIHR Health Technology Assessment programme Surgical treatments for women with stress urinary incontinence: the ESTER systematic review and economic evaluation
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma]leukemia]
2019     NIHR Health Technology Assessment programme Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: tisagenlecleucel for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia]
2019     NIHR Horizon Scanning Centre (NIHR HSC) An intervention to improve outcomes of falls in dementia: the DIFRID mixed-methods feasibility study
2019     Norwegian Institute of Public Health (NIPH) Organ donation with the use of normothermic regional perfusion in patients who die after cardiac and respiratory arrest after withdrawal of life-sustaining treatment
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: breast tomosynthesis and breast cancer screening]
2019     NIHR Health Technology Assessment programme Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: treatment of mitral regurgitation by a percutaneous device with clip (TMVRc)]
2019     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Stereotactic neurosurgery frameless. The iSYS1® Robotic device]
2019     Norwegian Institute of Public Health (NIPH) Disease modifying treatments for relapsing remitting multiple sclerosis. A health economic evaluation
2019     Norwegian Institute of Public Health (NIPH) Disease-modifying treatments for relapsing remitting multiple sclerosis, including rituximab. A health technology assessment
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: pharmacological treatment of sexually transmitted and blood-borne infections ─ external condylomas (anogenital warts)]
2019     Andalusian Health Technology Assessment Area (AETSA) PET usefulness in non-oncological indications
2019     Norwegian Institute of Public Health (NIPH) Prehospital CT for early diagnosis and treatment of suspected acute stroke or severe head injury
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: best strategies for reducing the risk of severe toxicities caused by dihydropyrimidine dehydrogenase deficiency]
2019     Andalusian Health Technology Assessment Area (AETSA) Clinical Utility of Procalcitonin–Guidance for initiation of antimicrobian treatment in patients admitted to the ICU
2019     Norwegian Institute of Public Health (NIPH) Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer. Assessment of manufacturer’s submission
2019     Norwegian Institute of Public Health (NIPH) Health technology assessment of Transcatether aortic valve implantation (TAVI) as treatment of patients with severe aortic stenosis and intermediate surgical risk – Part 2. Health economic evaluation
2019     Norwegian Institute of Public Health (NIPH) Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke
2019     Norwegian Institute of Public Health (NIPH) Hyperbaric oxygen therapy for osteonecrosis
2019     NIHR Public Health Research (PHR) programme Mass media to communicate public health messages in six health topic areas: a systematic review and other reviews of the evidence
2019     NIHR Health Technology Assessment programme Trial of Acute Femoral Fracture Fixation (TrAFFix). A feasibility study
2019     Adelaide Health Technology Assessment (AHTA) Alpha Thalassaemia genetic testing
2019     Swiss Federal Office of Public Health (FOPH) Self-measurement of blood glucose in patients with non-insulin treated diabetes mellitus type 2
2019     Swiss Federal Office of Public Health (FOPH) Assessment of knee arthroscopy for the treatment of degenerative changes
2019     NIHR Health Services and Delivery Research programme Innovation to enhance health in care homes: rapid evidence synthesis
2019     NIHR Health Services and Delivery Research programme Improving NHS quality using internet ratings and experiences (INQUIRE)
2019     NIHR Health Services and Delivery Research programme Evaluation of specialist nursing support for carers of people with dementia
2019     NIHR Health Services and Delivery Research programme Understanding and enhancing how hospital staff learn from and act on patient experience data
2019     NIHR Health Services and Delivery Research programme A study of sense-making strategies and help-seeking behaviours associated with the use and provision of urgent care services
2019     Center for Evidence-based Practice (CEP) The Effect of Patient Communication About Medical Errors on Malpractice Lawsuits
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
2019     Center for Evidence-based Practice (CEP) Interventions to Reduce the Use of the High Risk Medications in Elderly Patients
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis
2019     Center for Evidence-based Practice (CEP) Guidelines for Supplementary Feedings of Newborn Infants
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). EUnetHTA-Report
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections. EUnetHTA-Report
2019     NIHR Health Technology Assessment programme Treatment of first-time traumatic anterior shoulder dislocation UK.TASH-D Study
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Evaluation methods for the benefit assessment of easily accessible, outpatient health centres for vulnerable groups - Target group focus: Homeless and non-insured persons
2019     NIHR Health Services and Delivery Research programme The changing general practitioner workforce: the development of policies and strategies aimed at retaining experienced GPs and those taking a career break in direct patient care (ReGROUP)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Robot-assisted surgery in thoracic and visceral indications
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Alphanate - von Willebrand disease]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Annulus Fibrosus Repair after lumbar discectomy
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Single/two-step scaffold-based cartilage repair in the knee and ankle joint
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency denervation for lumbar and cervical facet joint pain – a systematic review
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea. 1st Update 2019
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Osteochondral allograft transplantation for the knee (or other joints)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Allograft for anterior and posterior cruciate ligament reconstruction
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Human dermal allograft for massive rotator cuff tears
2019     NIHR Health Services and Delivery Research programme PRESENT: Patient Reported Experience Survey Engineering of Natural Text: developing practical automated analysis and dashboard representations of cancer survey freetext answers
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate
2019     National Committee for Technology Incorporation (CONITEC) [Diagnostic tests for thrombophilia in pregnancy]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Custom-made or customisable 3D printed implants and cutting guides versus non- 3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Irreversible electroporation for the treatment of liver and pancreatic cancer
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Screening and prevention programmes for children and adolescents from 6 to 14 years. Results from selected countries and recommendations from evidence-based guidelines
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Screening for Diabetes mellitus: guideline recommendations
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) FoundationOne®CDx: genetic profiling of solid tumours
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pharma: Disclosure of transfers of value in Austria 2018. Update of the systematic analysis 2015
2019     NIHR Health Technology Assessment programme Cabozantinib and vandatinib for treating advanced or metastatic medullary thyroid cancer (ID56)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Screening programs for children and adolescents from 6 to 18 years. Results on selected countries, Austrian screening programmes and recommendations from evidence-based guidelines
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies
2019     NIHR Health Technology Assessment programme An evaluation of the feasibility of conducting a randomised clinical trial to evaluate the clinical and cost-effectiveness of a more permissive temperature threshold for antipyretic intervention in critically ill children with fever due to infection: the FEVER feasibility study
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge, state of practice: Use of direct oral anticoagulants and warfarin in the context of atrial fibrillation and venous thromboembolism]
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) POCT/ Point of Care Tests: D-Dimer and Troponin
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: anticoagulant therapy]